$CD19^+IgD^+CD27^-$ naïve B Cells as predictors of humoral response to COVID-19 mRNA vaccination in immunocompromised patients

Eduard Schulz[1*], Isabel Hodl[2*], Patrick Forstner[3], Stefan Hatzl[1], Nazanin Sareban[4], Martina Moritz[4], Johannes Fessler[5], Barbara Dreo[2], Barbara Uhl[1], Claudia Url[4], Andrea Grisold[3], Michael Khalil[6], Barbara Kleinhappl[3], Christian Enzinger[6], Martin H. Stradner[2], Hildegard Greinix[1], Peter Schlenke[4] and Ivo Steinmetz[3]

*ES and IH contributed equally to the manuscript.

[1]Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
[2]Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
[3]Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria
[4]Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria
[5]Institute of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
[6]Department of Neurology, Medical University of Graz, Graz, Austria

Corresponding author:

Martin H. Stradner
Division of Rheumatology and Immunology
Department of Internal Medicine
Medical University of Graz
Auenbruggerplatz 15, 8036 Graz, Austria
Tel: +43/316/385-81794
Fax: +43/316/385-17813
E-mail: martin.stradner@medunigraz.at

The authors declare no competing financial interests.

Key words: mRNA vaccine, COVID-19, B cells, cancer, immunodeficiency

ABSTRACT

Immunocompromised patients are considered high-risk and prioritized for vaccination against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential predictors of humoral vaccination response. Patients (n=120) suffering from hematologic malignancies or other causes of immunodeficiency and healthy controls (n=79) received a full vaccination series with an mRNA vaccine. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination. Seroconversion occurred in 100% of healthy controls, in contrast to 67% (RBD) and 82% (TSP) of immunocompromised patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating $CD19^{+}IgD^{+}CD27^{-}$ naïve B cells was strongly associated with antibody levels (ρ=0.761, P<0.001) and the only independent predictor for achieving antibody levels comparable to healthy controls (OR 1.07 per 10-µl increase, 95%CI 1.02–1.12, P=0.009). Receiver operating characteristic analysis identified a cut-off at ≥61 naïve B cells per µl to discriminate between patients with and without an optimal antibody response. Consequently, measuring naïve B cells in immunocompromised hematologic patients could be useful in predicting their humoral vaccination response.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) results in increased morbidity and mortality in immunocompromised patients.(1-3) Immunodeficiency can be primary (PID) due to underlying genetic causes such as common variable immunodeficiency or secondary (SID) resulting from hematologic malignancies (HM), immunosuppressive therapies, or hematopoietic stem cell transplantation (HSCT). In a recent study of 100 patients with COVID-19 disease, patients with PID and SID demonstrated higher morbidity and mortality than the general population, while the outcomes of individuals suffering from SID were the worst.(1) In patients with HM and COVID-19, a mortality rate of 34% (95% confidence interval [CI]: 28–39) has been reported in adults in a recent meta-analysis including 3377 predominantly hospitalized patients from 3 continents.(4) Interestingly, patients on systemic anticancer treatment had a similar risk of death compared to patients without therapy (RR 1.17, 95% CI: 0.83-1.64). Risk of death was highest in patients with acquired bone marrow failure syndromes (53%, 95% CI: 34-72), followed by acute leukemias (41%, 95% CI: 30-52), myeloproliferative neoplasms (34%, 95% CI: 19-51), plasma cell dyscrasias (33%, 95% CI: 25-41), lymphomas (32%, 95% CI: 18-48), and chronic lymphocytic leukemias (CLL) (31%, 95% CI: 23-40), respectively.

Patients with HM can be immunocompromised due to the underlying malignancy itself, prior or ongoing treatments with a high degree of immunosuppressive effects such as corticosteroids, B-cell depleting therapies, HSCT and other cellular therapies. In individuals with these risk factors, lower rates of seroconversion have been reported after COVID-19 infection whereas other cancer patients developed antibody response similar to healthy individuals.(5, 6) Roeker and colleagues observed that 67% of patients with CLL developed IgG antibodies to SARS-CoV-2 nucleocapsid and the seroconversion rate among recipients of HSCT and chimeric antigen receptor (CAR) T-cell therapy was similar at 66%.(7, 8)

Due to the high risk of severe COVID-19 in immunocompromised patients, they are considered a high priority for COVID-19 vaccination.(9-13) However, trials of the currently approved COVID-19 vaccines have excluded individuals diagnosed with immunodeficiency or malignancy; therefore, information on the efficacy and safety of the vaccines in these patients is sparse.(14-17) It is well known

that vaccinations in patients early after HSCT and anti-CD20 therapies as well as with several forms of PID have low efficacy.(18-20) The humoral immune response to a recombinant zoster vaccine in patients with B-cell lymphoma and CLL was between 20% and 50% compared to 80% in patients with other HM.(21)

Lack of antibody responses after COVID-19 vaccination and significantly lower antibody levels in responders have been reported in HM patient cohorts in general(5, 22, 23) and in selected patients with multiple myeloma, CLL, and non-Hodgkin's lymphoma.(24-28) Low efficacy of COVID-19 vaccinations was observed when administered soon after HSCT and anti-CD20 therapies.(9, 18, 19) Furthermore, immunocompromised patients due to inborn errors of immunity or autoimmune rheumatic disease (AIRD) demonstrated also reduced rates in seroconversion, especially when given B-cell-depleting therapy and glucocorticoids.(14-17)

Peripheral B cells are needed for humoral vaccination responses.(29) However, the number of circulating B cells or of a certain B-cell subset associated with a humoral vaccination response comparable to healthy individuals is unknown. A marker predictive of vaccination response would aid to schedule vaccinations in the immunocompromised patients to achieve an optimal vaccination response.

We hypothesize that specific B-cell subsets have to be present in immunocompromised individuals to enable a humoral vaccination response. Herein, we used data from an interim analysis of the prospective, open-label, phase IV CoVVac trial (NCT04858607) to test this hypothesis.

MATERIALS AND METHODS

Study design and participants

We report the data of an interim analysis of the CoVVac trial (NCT04858607), which is an ongoing open-label, phase IV, prospective, monocentric study at the Medical University of Graz, Austria. After approval by the ethics committee of the Medical University of Graz in April 2021 (EK 1128/2021), patients with inborn errors of immunity, hematological malignancies, those receiving B-cell-depleting therapy, and healthy controls were recruited before receiving their first dose of COVID-19 vaccine. The

54 detailed study protocol is provided in the Supplementary Information. In brief, blood was drawn before
55 the first vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) for peripheral blood
56 mononuclear cell (PBMC) isolation and lymphocyte phenotyping. The second vaccination was
57 administered 21 (BNT162b2) or 28 days (mRNA-1273) after the first. Blood sampling was performed
58 21–28 days after the second vaccination to analyze the COVID-19-specific antibody response as the
59 primary endpoint.

60 Lymphocyte phenotyping

61 Blood samples from the baseline visit were processed within 4 hours for analysis by flow cytometry.
62 For lymphocyte phenotyping, ethylenediaminetetraacetic acid whole blood was stained for CD3, CD4,
63 CD8, CD45, CD16, CD56, and CD19, as previously described.(30) For B-cell phenotyping, PBMCs
64 were isolated from lithium heparin whole blood by Ficoll gradient density centrifugation. One million
65 PBMCs were incubated with the following antibodies: CD19-VioGreen, anti-IgD-VioBlue, CD24-
66 PerCP-Vio700, CD38-FITC, CD27-APC, CD86-PE-Vio770, CD21-APC-Vio770, and anti-IgM-PE
67 (Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were measured using a FACSLyric flow
68 cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using the FACSSuite (BD
69 Biosciences). The gating strategy is shown in Supplemental Figure 1.

70 Antibody assays

71 Blood was obtained before first and 21–28 days after the second vaccination. Serum was aliquoted,
72 frozen, and stored at -80°C until analysis was performed in batches. Two commercially available CE-
73 certified serological tests were performed according to the manufacturers' protocols to determine and
74 quantify specific antibodies against SARS-CoV-2. Specific IgG was determined using the Roche
75 Elecsys anti-SARS-CoV-2 S electrochemiluminescence immunoassay targeting the receptor-binding
76 domain of the viral spike protein using a Cobas e 801 analytical unit (Roche Diagnostics GmbH,
77 Mannheim, Germany).(27, 29) Its quantification range lies between 0.4 and 2500 U/ml, with a cut-off
78 of 0.8 U/ml for positivity. Specific IgG was measured by Liaison SARS-CoV-2 TrimericS IgG test on
79 Liaison XL (DiaSorin, Saluggia, Italy), which is a chemiluminescence immunoassay quantifying

antibodies that target the trimeric S protein.(28) Results are provided in binding antibody units (BAU) with a quantification range of 4.81–2080 BAU/ml. Values ≥33.8 BAU/ml were considered positive.

Statistical analysis

All statistical analyses were performed using Stata 16.1 (Stata Corp., Houston, TX, USA). Continuous data were reported as medians (25th–75th percentile) and categorical data as absolute frequencies (%). Correlations and associations between antibody response and other variables were examined using Spearman's rank-based correlation coefficients, rank-sum test, and χ^2-squared tests. R^2-statistics were obtained from multiple linear regression models with antibody response as the dependent variable. The optimal cut-off to separate patients with and without vaccination response was assessed by employing a maximized Youden's index within a receiver operating characteristic (ROC) analysis. Logistic models were used for univariate and multivariate modeling of the vaccination response. The Kruskal–Wallis test was used for continuous variables when comparing three or more treatment groups. The Kruskal-Wallis H test was used as a post-hoc test to determine between-group differences.

RESULTS

Study population

Data of 199 study participants who completed their full vaccination schedule were included in the efficacy analysis. Of these, 79 were healthy participants and 120 were immunocompromised patients. All study participants were vaccinated with mRNA-1273, with only two healthy individuals (1%) receiving BNT162b2. A total of 140 adverse events occurred after vaccination, with the most common being pain at the injection site, headache, fever, and fatigue. Four severe adverse events (hospitalization and death due to HM and bone fractures) were considered unrelated to vaccination. Participant characteristics are listed in Table 1. Diagnoses, immunosuppressive treatments, and antibody responses for subgroups are detailed in Supplementary Table 1.

106 **Table 1.**

Variable	Healthy (n=79)	Immunocompromised (n=120)	P
Age (years)	51 [36-56]	58 [50-65]	**<0.001**
Female gender n (%)	45 (57)	65 (54)	0.698
Body mass index (kg/m²)	23.7 [21.6-26.4]	24.8 [22.7-27.8]	**0.039**
Vaccine			0.080
mRNA-1273 (Moderna)	77 (97)	120 (100)	
BNT162b2 (BioNTech/Pfizer)	2 (3)	0 (0)	
Immunodeficiency group			n/a
Primary immunodeficiency n (%)		25 (21)	
Autoimmune disease n (%)		39 (32)	
Hematologic disease n (%)		56 (47)	
B-cell depleting therapy			n/a
None n (%)		44 (37)	
Rituximab n (%)		35 (29)	
Ocrelizumab n (%)		6 (5)	
HSCT n (%)		35 (29)	
Days since B-cell depletion		166 [69-545]	

107 **Table 1**. Baseline characteristics of the study population. Data are reported as medians [25th-
108 75th percentile] and absolute frequencies (%). P-values are from rank-sum tests, $\chi 2$-tests, and Fisher's
109 exact tests, as appropriate. Significant P-values are highlighted in bold type. Abbreviations: n, number;
110 HSCT, hematopoietic stem cell transplantation

111 Immunogenicity of mRNA vaccines

112 Antibody responses were assessed using two different assays. All healthy controls demonstrated
113 seroconversion with high antibody titers (Roche median: 2500 U/ml; DiaSorin median: 2080 BAU/ml).
114 In immunocompromised patients, the seroconversion rates and antibody levels were significantly lower
115 than those in healthy controls (Table 2 and Figure 1); 67% (n = 80) and 82% (n = 98) of patients
116 demonstrated a humoral response with antibody levels within the quantification range of Roche and
117 DiaSorin assays, respectively. Since the clinical significance of antibody levels close to the limit of
118 detection was unclear, we defined more stringent thresholds for our patients, namely a "stringent
119 response" as reaching at least the lowest antibody level of the healthy individuals from our cohort (Roche
120 ≥1000 U/ml; DiaSorin ≥2000 BAU/ml). According to this definition, only 32% (Roche) and 22%

121 (DiaSorin) of patients had a stringent antibody response. This difference was not statistically significant
122 between the two tests (P = 0.108). Patients who received anti-CD20 therapy, including the majority of
123 patients with AIRD, had the lowest rate of stringent response (≤10%). Interestingly, patients who
124 received HSCT demonstrated a relatively high rate of stringent response [37% (13/35)]. There was no
125 statistically significant difference between allogeneic and autologous HSCT (40% vs. 30%, respectively;
126 P = 0.541). The antibody levels of both assays showed an excellent correlation with each other in the
127 patient population ($\rho = 0.915$, $P<0.001$, $R^2 = 0.841$; Table 2; Figure 2A), as well as in the entire study
128 population (Supplementary Figure 2A). Since the Roche assay is more widely used in research and
129 shows a good correlation with live virus neutralization tests in vaccinated individuals(22, 27, 29, 31),
130 we focused on the Roche assay for subsequent analyses to ensure comparability with other studies.

131 **Table 2.**

	Healthy (n=79) N (%)	**Immunocompromised (n=120) N (%)**	**P**
Roche any response	79 (100)	80 (67)	**<0.001**
Roche stringent response	79 (100)	38 (32)	**<0.001**
Roche U/ml	2500 [2500-2500]	67 [0-1947]	**<0.001**
DiaSorin any response	79 (100)	98 (82)	**<0.001**
DiaSorin stringent response	79 (100)	26 (22)	**<0.001**
DiaSorin BAU/ml	2080 [2080-2080]	233 [12-1760]	**<0.001**

132 **Table 2**. Antibody Response to Vaccination. Data are reported as medians [25th-75th percentile]
133 and absolute frequencies (%). P-values are from rank-sum tests, $\chi 2$-tests, and Fisher's exact tests, as
134 appropriate. Significant P-values are highlighted in bold type. Any response, any seroconversion; BAU,
135 binding antibody unit; DiaSorin stringent response, DiaSorin SARS-CoV-2 TrimericS IgG ≥2000
136 BAU/ml; HSCT, hematopoietic stem stell transplantation; Roche stringent response, Roche anti-SARS-
137 CoV-2 S total antibody titer ≥1000 U/ml.

138

139 ## Correlation of antibody levels with the amount of B-cell subsets

140 The total number of B cells and all B-cell subsets prior vaccination were positively correlated with the
141 antibody levels in all patients (Roche: $\rho = 0.739$, $R^2 = 0.001$, $P<0.001$; Table 3; Figure 2B). In this
142 analysis, the absolute number of naïve B cells showed the highest correlation with antibody titers
143 (Roche: $\rho = 0.761$, $R^2 = 0.153$; Figure 2C). Furthermore, this analysis also indicated that the time
144 between last B-cell-depleting therapy and vaccination was also a significant factor correlating with
145 antibody levels. Extending this correlation analysis to the entire study population (Supplementary Figure
146 2), the influence of naïve B cells remained highly significant (Roche: $\rho = 0.636$, $P<0.001$, $R^2 = 0.123$).

147 To support the results of our correlation analyses, we established a model of stringent vaccination
148 response prediction for the entire study population based on the results of the Roche assay using the area
149 under the ROC curve (AUC; Supplementary Table 2). This model suggests that the total number of
150 $CD19^+$ B cells (AUC: 0.87, 95% CI: 0.79–0.92), $CD19^+IgD^+CD27^-$ naïve B cells (AUC: 0.82, 95% CI:
151 0.73–0.88), $CD19^+IgD^+CD27^+$ pre-switched memory B cells (AUC: 0.84, 95% CI: 0.76–0.89), and
152 $CD19^+IgD^-CD27^+$ switched memory B cells (AUC: 0.85, 95% CI: 0.79–0.91) can predict response to
153 vaccination in the entire study population.

154

155 **Table 3.**

Variable	**Roche anti-SARS-CoV-2**		
	ρ	**P**	**R^2**
DiaSorin SARS-CoV-2 TrimericS IgG	0.915	**<0.001**	0.841
Age	0.091	0.321	0.001
Body mass index	0.169	0.076	0.004
Days since last B-cell depletion	0.595	**<0.001**	0.041
Interval in days from last B-cell depleting therapy to vaccination up to 365 days	0.481	**0.001**	0.096
IgA	0.042	0.651	0.015
IgG	0.065	0.481	0.031
IgM	0.386	**<0.001**	0.002
Lymphocytes abs.	0.222	0.018	0.002
$CD3^+$ cells abs.	0.112	0.236	0.034
$CD3^+CD8^+$ cells abs.	0.170	0.071	0.005
$CD3^+CD4^+$ cells abs.	0.025	0.789	0.062
$CD3^-CD16^+CD56^+$ NK cells abs.	-0.014	0.880	0.014
$CD19^+$ abs.	0.739	**<0.001**	0.001
$CD45^+$ cells abs.	0.227	0.015	0.002
$CD19^+IgM^+CD38^{++}$ transitional B cells abs.	0.491	**<0.001**	0.033
$CD19^+IgD^+CD27^-$ naïve B cells abs.	0.761	**<0.001**	0.153
$CD19^+IgD^+CD27^+$ pre-switched memory B cells abs.	0.657	**<0.001**	0.004
$CD19^+IgD^-CD27^+$ switched memory B cells abs.	0.710	**<0.001**	0.003
$CD19^+CD38^-CD21^-$ B cells abs.	0.640	**<0.001**	0.001
$CD19^+IgM^-CD38^{++}$ plasmablasts abs.	0.580	**<0.001**	0.001

156 **Table 3**. Correlations of SARS-CoV-2 antibody response with variables in the
157 immunocompromised study population. Correlations were computed with Spearman's rank-based rho
158 adjusted for multiple testing (n=21) with Šidák correction. The Šidák-adjusted α level is approximately
159 0.00244. Significant P-values are highlighted in bold type. Abs., absolute count.

160

161 ## $CD19^+IgD^+CD27^-$ naïve B cells show the strongest association with

162 ## stringent response

163 To test the association of variables with vaccination response determined by the Roche assay, we
164 performed univariate and multivariate linear regression analyses using the same variables from the
165 correlation analyses.

166 In univariate analysis (Table 4), the variables found to be significantly associated with any antibody
167 response in patients included interval in days from the last B-cell-depleting therapy, $CD19^+IgD^+CD27^-$
168 naïve B-cell count, $CD19^+IgD^+CD27^+$ pre-switched memory B-cell count, and absolute number of
169 $CD19^+IgM^-CD38^{++}$ plasmablasts. The same correlation was also found for stringent antibody responses,
170 except for the correlation with $CD19^+IgD^+CD27^+$ pre-switched memory B cells. The absolute number
171 of these B-cell subsets was significantly lower in immunocompromised patients than in healthy controls,
172 in patients after anti-CD20 antibody therapy compared to HSCT, and in patients without seroconversion
173 compared to those with any antibody response (not shown) or stringent response (Supplementary Figure
174 3). Immunoglobulin levels and cell counts of immunodeficient patients stratified by vaccination
175 response are shown in Supplementary Table 3. In univariate analysis of the entire study population
176 (Supplementary Table 4), the same B-cell subsets remained significantly associated with vaccine
177 response.

178 In multivariable analysis for stringent response, only the number of $CD19^+IgD^+CD27^-$ naïve B cells was
179 an independent predictor (OR: 1.07 per 10-µl increase, 95% CI: 1.02–1.12, P = 0.009). The only
180 independent predictor of any seroconversion was $CD19^+IgM^-CD38^{++}$ plasmablast count (OR: 4.42 per
181 1-µl increase, 95% CI: 1.30–15.01, P = 0.017).

182 The multivariable analyses for the entire study population are shown in Supplementary Tables 5 and 6.
183 The absolute number of $CD19^+IgD^+CD27^-$ naïve B cells remained an independent predictor of stringent
184 antibody response (OR: 1.14 per 10-µl increase, 95% CI: 1.08–1.20, P<0.001).

185

186

187 **Table 4.**

Variable	Any Response			Stringent Response		
	OR	**95% CI**	**P**	**OR**	**95% CI**	**P**
Age (per 10 years)	1.23	0.92-1.66	0.167	1.02	0.76-1.38	0.880
Body mass index (per 5 point)	1.20	0.77-1.87	0.420	1.11	0.71-0.73	0.633
Interval in days from last B-cell depleting therapy to vaccination up to 365 days (per 30 days)*	1.41	1.13-1.76	**0.002**	1.31	1.02-1.67	**0.035**
IgA (per 1g/l)	0.74	0.50-1.10	0.136	1.30	0.87-1.93	0.199
IgG (per 5g/l)	0.96	0.62-1.49	0.848	1.43	0.90-2.27	0.127
IgM (per 1g/l)	1.32	0.83-2.10	0.246	0.98	0.92-1.05	0.677
Lymphocytes abs. (per 1 G/l)	0.94	0.81-1.10	0.461	1.03	0.89-1.18	0.686
$CD3^+$ cells abs. (per 10/µl)	1.00	0.99-1.01	0.693	1.00	0.99-1.01	0.101
$CD3^+CD8^+$ cells abs. (per 10/µl)	1.01	0.99-1.02	0.143	1.00	0.99-1.01	0.846
$CD3^+CD4^+$ cells abs. (per 10/µl)	0.99	0.98-1.01	0.403	1.01	1.00-1.02	0.009
$CD3^-CD16^+CD56^+$ NK cells abs. (per 10/µl)	0.98	0.96-1.01	0.139	1.01	0.99-1.03	0.180
$CD19^+$ abs. (per 10/µl)	0.99	0.99-1.01	0.401	0.99	0.99-1.01	0.931
$CD45^+$ cells abs. (per 10/µl)	0.99	0.99-1.01	0.045	1.00	0.99-1.01	0.653
$CD19^+IgM^+CD38^{++}$ transitional B cells abs. (per 1/µl)	1.17	0.97-1.42	0.094	1.05	0.96-1.15	0.233
$CD19^+IgD^+CD27^-$ naïve B cells abs. (per 10/µl)	1.17	1.07-1.28	**0.001**	1.09	1.04-1.14	**<0.001**
$CD19^+IgD^+CD27^+$ pre-switched memory B cells abs. (per 10/µl)	1.78	1.09-2.92	**0.021**	1.03	0.95-1.11	0.480

$CD19^{+}IgD^{-}CD27^{+}$ switched memory B cells abs. (per 10/µl)	0.99	0.99-1.01	0.406	0.99	0.99-1.00	0.957
$CD19^{+}CD38^{-}CD21^{-}$ B cells abs. (per 10/µl)	0.99	0.98-1.01	0.512	1.00	0.99-1.01	0.746
$CD19^{+}IgM^{-}CD38^{++}$ plasmablasts abs. (per 1/µl)	7.95	2.68-23.4	**<0.001**	1.85	1.24-2.74	**0.002**

Table 4. Univariate linear regression analysis to test the association of variables with vaccination response determined by the Roche anti-SARS-CoV-2 S assay in the immunodeficient cohort. Significant P-values are highlighted in bold type. Any response, any seroconversion; OR, odds ratio; stringent response, total antibody titer ≥1000 U/ml. Abs., absolute count.

Exploratory analyses

As $CD19^{+}IgD^{+}CD27^{-}$ naïve B cells were the only B-cell subset independently associated with stringent antibody response, we were interested to determine whether our dataset allowed to estimate a $CD19^{+}IgD^{+}CD27^{-}$ naïve B cell count threshold for stringent antibody response. ROC analysis and non-linear risk modeling predicted that ≥61 $CD19^{+}IgD^{+}CD27^{-}$ naïve B cells per µl discriminated best between patients with and without a stringent vaccine response (Figures 3A, B).

A second exploratory ROC analysis was undertaken to determine the minimum interval between last B-cell-depleting therapy, i.e., anti-CD20 antibody therapy or HSCT up to 365 days (n = 53), and vaccination differentiating any seroconversion versus no vaccination response. The optimal cut-off in this population was 116 days or more (Figure 3C).

DISCUSSION

Since the presence of B cells is a prerequisite for humoral vaccination responses, we investigated B cells overall and multiple B-cell subsets in immunocompromised patients and healthy controls prior to COVID-19 mRNA vaccination.

207 Our findings confirm recent reports observing significantly lower and more heterogeneous anti-SARS-
208 CoV-2 S protein IgG titers in immunocompromised patients compared to healthy controls.(14, 15, 22,
209 24-29) In one of the largest studies, Maneikis and colleagues reported lower median anti-S1 IgG
210 responses after two BNT162b2 vaccine doses in 653 patients with HM compared to 69 healthy
211 healthcare workers.(23) A similar heterogeneity in vaccination response has been observed in patients
212 with PID,(14) AIRD,(16) and individuals given anti-CD20 therapy.(22, 23, 27, 32) In view of the
213 heterogeneity of anti-SARS-CoV-2 antibody levels and the current lack of knowledge regarding the
214 clinical consequences of low versus high titers in immunocompromised patients, we additionally
215 analyzed stringent vaccination response defined as the lowest anti-SARS-CoV-2 antibody titers
216 observed in our healthy control assuming that these would be protective. Based on this definition, only
217 32% (Roche) and 22% (DiaSorin) of our patients demonstrated a stringent antibody response,
218 respectively. Longitudinal studies are on their way to assess durability of anti-SARS-CoV-2 humoral
219 responses as well as incidences of COVID-19 infections in patients with or without stringent humoral
220 response.

221 In our study, absolute numbers of $CD19^{+}IgD^{+}CD27^{-}$ naïve B cells, $CD19^{+}IgD^{+}CD27^{+}$ pre-switched
222 memory B cells, and $CD19^{+}IgM^{-}CD38^{++}$ plasmablasts were significantly associated with anti-
223 SARS-CoV-2 response in univariate analysis. However, only the number of $CD19^{+}IgD^{+}CD27^{-}$ naïve B
224 cells was an independent predictor of a stringent vaccination response in multivariable analysis,
225 suggesting their functional importance for obtaining a humoral immune response. Indeed, the production
226 of specific antibodies to a novel antigen relies on the presence of antigen-specific B cells within the
227 $CD19^{+}IgD^{+}CD27^{-}$ naïve B cell population.(33) Thus, a drastically contracted pool of $CD19^{+}IgD^{+}CD27^{-}$
228 naïve B cells reduces the chance of harboring B cells with a B-cell receptor of high antigen avidity that
229 can interact with T follicular helper cells successfully and subsequently undergo somatic hypermutation
230 to develop an optimal antibody response.(34) A lack of these cells results in low antibody titers of poor
231 quality. Therefore, the association of the magnitude of the humoral vaccination response with the
232 abundance of $CD19^{+}IgD^{+}CD27^{-}$ naïve B cells is most likely a causal relationship.

233 To date, there is little literature on this topic, and we are the first to describe this relationship, particularly
234 in the context of COVID-19 and immunocompromised patients. The importance of naïve B cells for

235 antibody response has already been shown for the H5N1 influenza vaccine, but to the best of our
236 knowledge not yet for immunocompromised patient cohorts or COVID-19 in particular.(35) Recently,
237 Redjoul and colleagues reported a significant increase in anti-SARS-CoV-2 antibodies in 42 HM
238 patients given a third dose of BNT162b2 vaccine after allogeneic HSCT.(36) In a multivariable analysis,
239 only a peripheral B-cell count of more than 250/µl at the time of the third vaccination was associated
240 with humoral response (OR 7.1, 95% CI: 1.5-34.1, P=0.016).(36) Mrak et al. observed that the
241 percentage of peripheral $CD19^+$ B cells positively correlated with antibody levels after BNT162b2
242 vaccination (τ=0.4, P<0.001) in patients with AIRD after rituximab therapy.[24] The median percentage
243 of peripheral $CD19^+$ B cells was 2% (interquartile range [IQR], 0-33) in the study of Mrak et al., which
244 is not very different from 4% (IQR, 0-13) in our patient population. Our results extend these findings
245 and show that only $CD19^+IgD^+CD27^-$ naïve B cells predicted a strong vaccination response.

246 How soon humoral immune responses may be expected after B-cell depleting therapy remains a concern,
247 and recommendations of medical societies differ. Our data confirm that the interval between the last B-
248 cell-depleting therapy and SARS-CoV-2 vaccination plays a crucial role in achieving seroconversion
249 for immunocompromised patients. We were able to define a minimum of 116 days, i.e. 4 months, from
250 last B-cell-depleting therapy to vaccination as prerequisite for obtaining an anti-SARS-CoV-2
251 seroconversion.

252 Whereas patients after allogeneic HSCT have high numbers of $CD19^+IgD^+CD27^-$ naïve B cells, this
253 B-cell subpopulation was significantly lower in individuals suffering from chronic graft-versus-host
254 disease (GVHD).(37) Long-term clinical efficacy of rituximab could be demonstrated in chronic GVHD
255 patients recovering naïve B cells after treatment. These findings are consistent with clinical responses
256 to rituximab reported in patients with rheumatoid arthritis, SLE, and mixed cryoglobulinemia who
257 recovered B cells.(38-40) Thus, rise in absolute numbers of B cells as well as $CD19^+IgD^+CD27^-$ naïve
258 B cells might indicate immune reconstitution after immunosuppressive therapies enabling achievement
259 of a humoral immune response to SARS-CoV-2 vaccination. Contrarily, patients with a deficit of
260 $CD19^+IgD^+CD27^-$ naïve B cells may benefit more from continuation of strict hygiene measures as
261 recommended by scientific organizations. Whether these immunocompromised patients will

262 substantially benefit from a third vaccination, must be demonstrated since first data of HSCT patients
263 showed only low antibody titers in half of the patients.(36)

264 Our study had several limitations. These include single-center design and limited representation of some
265 patient cohorts that do not allow clear conclusions on seroconversion rates among less common entities
266 or less frequently used treatment strategies. Moreover, we cannot comment on the persistence of the
267 observed vaccination response at this point. Our study relies on the measurement of antibodies as a
268 surrogate for immunity to SARS-CoV-2. However, our results do not significantly differ between the
269 two internationally deployed anti-spike protein serological assays for detecting either total Ig or IgG.
270 Both tests showed a high correlation with surrogate neutralization tests, and Roche's assay correlated
271 well with live virus neutralization tests in vaccinated individuals.(29, 31) The strength of our study is
272 its prospective design and the introduction of the stringent vaccination response as a potentially
273 clinically more relevant concept than seroconversion.

274 In summary, humoral response to SARS-CoV-2 mRNA vaccine is impaired in immunocompromised
275 patients. The abundance of circulating $CD19^{+}IgD^{+}CD27^{-}$ naïve B cells is strongly associated with an
276 improved antibody vaccine response across different diseases and therapies. Therefore, measuring
277 $CD19^{+}IgD^{+}CD27^{-}$ naïve B cells may allow prediction of a humoral response to COVID-19 vaccination
278 in immunocompromised patients. Further research is needed to confirm these findings for vaccinating
279 immunocompromised individuals against COVID-19 and other pathogens.

280 **Acknowledgments**

281 We thank Pia-Carina Gallaun and Julia Lodron for technical assistance. The samples/data used for this
282 project were processed with the help of the Biobank Graz of the Medical University of Graz, Austria.

283 **Competing Interests**

284 None of the contributing authors have a conflict of interest, including specific financial interests,
285 relationships, and affiliations relevant to the topic or materials covered in the manuscript.

286 **Author contributions**

287 IH, ES, PS, SH, HG, IS, and MHS designed the study. ES, IH, PF, NS, JF, BD, BU, AG, MM, CU, MK,
288 CE and BK collected clinical samples and/or data. PF and BK performed antibody assays. ES and SH

289 analyzed the data and performed the statistical analysis. ES, SH, IH, PS, HG, IS, and MHS critically
290 reviewed and discussed the results. ES, IH, PF, HS, HG, and MHS wrote the first draft. All authors
291 reviewed the draft and approved the final version of the manuscript.

292 **REFERENCES**

293 1. Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients
294 with primary and secondary immunodeficiency: The United Kingdom experience. *J Allergy Clin*
295 *Immunol* 2021; **147**: 870,875.e1.

296 2. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR*, et al*. Clinical impact of
297 COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020; **395**: 1907-18.

298 3. Hatzl S, Eisner F, Schilcher G, Kreuzer P, Gornicec M, Eller P*, et al*. Response to "COVID-19 in
299 persons with haematological cancers". *Leukemia* 2020; **34**: 2265-70.

300 4. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B*, et al*. Outcomes of patients with
301 hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.
302 *Blood* 2020; **136**: 2881-92.

303 5. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K*, et al*. Seroconversion
304 rates following COVID-19 vaccination among patients with cancer. *Cancer Cell* 2021;.

305 6. Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S*, et al*. Seroconversion in patients
306 with cancer and oncology health care workers infected by SARS-CoV-2. *Ann Oncol* 2021; **32**: 113-9.

307 7. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA*, et al*. Anti-SARS-
308 CoV-2 antibody response in patients with chronic lymphocytic leukemia. *Leukemia* 2020; **34**: 3047-9.

309 8. Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA*, et al*. Favorable outcomes of COVID-
310 19 in recipients of hematopoietic cell transplantation. *J Clin Invest* 2020; **130**: 6656-67.

311 9. Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, *et al*. COVID-19 vaccine-readiness
312 for anti-CD20-depleting therapy in autoimmune diseases. *Clin Exp Immunol* 2020; **202**: 149-61.

313 10. Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, *et al*. Priority COVID-19
314 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. *Cancer Discov* 2021; **11**: 233-
315 6.

316 11. van der Veldt, A A M, Oosting SF, Dingemans AC, Fehrmann RSN, GeurtsvanKessel C, Jalving M,
317 *et al*. COVID-19 vaccination: the VOICE for patients with cancer. *Nat Med* 2021; **27**: 568-9.

318 12. Ameratunga R, Longhurst H, Steele R, Lehnert K, Leung E, Brooks AES, *et al*. Common Variable
319 Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic
320 COVID-19. *J Allergy Clin Immunol Pract* 2021;.

321 13. Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, *et al*. Point of view
322 on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
323 *RMD Open* 2021; **7**: e001594. doi: 10.1136/rmdopen-2021.

324 14. Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, *et al*. Immunogenicity of Pfizer-
325 BioNTech COVID-19 vaccine in patients with inborn errors of immunity. *J Allergy Clin Immunol* 2021;.

326 15. Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, *et al*. Disease activity
327 and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer
328 mRNA vaccine against SARS-CoV-2. *Ann Rheum Dis* 2021;.

329 16. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, *et al*. Immunogenicity and safety
330 of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory
331 rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis* 2021;.

332 17. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, *et al*. Effect of
333 Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective
334 Cohort Study. *Ann Intern Med* 2021;.

335 18. Jaffe D, Papadopoulos EB, Young JW, O'reilly RJ, Prockop S, Kernan NA, *et al*. Immunogenicity
336 of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic
337 cell (HC) transplants. *Blood* 2006; **108**: 2470-5.

338 19. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, *et al*. 2013 IDSA clinical
339 practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014; **58**: e44-100.

340 20. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena, M T,
341 *et al*. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. *J*
342 *Allergy Clin Immunol Pract* 2016; **4**: 38-59.

343 21. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, *et al*. Immunogenicity and
344 safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase
345 3, randomised, clinical trial and post-hoc efficacy analysis. *Lancet Infect Dis* 2019; **19**: 988-1000.

346 22. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody
347 response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell* 2021;.

348 23. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, *et al*.
349 Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients
350 with haematological malignancies in Lithuania: a national prospective cohort study. *Lancet Haematol*
351 2021; **8**: e583-92.

352 24. Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, *et al*. Humoral response rate and
353 predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. *Br*
354 *J Haematol* 2021;.

355 25. Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, *et al*. Response to first vaccination against
356 SARS-CoV-2 in patients with multiple myeloma. *Lancet Haematol* 2021; **8**: e389-92.

357 26. Gavriatopoulou M, Terpos E, Kastritis E, Briasoulis A, Gumeni S, Ntanasis-Stathopoulos I*, et al*.
358 Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the
359 BNT162b2 and AZD1222 vaccine. *Clin Exp Med* 2021;: 1-5.

360 27. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y*, et al*. Efficacy of the BNT162b2
361 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood* 2021; **137**: 3165-73.

362 28. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P*, et al*. Fifth-week
363 immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma
364 and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J*
365 *Hematol Oncol* 2021; **14**: 81-021.

366 29. Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D*, et al*. SARS-CoV-2
367 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence
368 of T-cell-mediated immunity. *Ann Rheum Dis* 2021;.

369 30. Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP. A combination of cellular
370 biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational
371 study. *Arthritis Res Ther* 2016; **18**: 190-016.

372 31. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R*, et al*. Anti-
373 Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five
374 Quantitative Assays. *Microbiol Spectr* 2021;: e0024721.

375 32. Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L*, et al*. BNT162b2
376 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. *Am J*
377 *Hematol* 2021;.

378 33. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol*
379 2009; **9**: 185-94.

380 34. Chan TD, Brink R. Affinity-based selection and the germinal center response. *Immunol Rev* 2012;
381 **247**: 11-23.

382 35. Ellebedy AH, Nachbagauer R, Jackson KJL, Dai YN, Han J, Alsoussi WB*, et al*. Adjuvanted H5N1
383 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses
384 in humans. *Proc Natl Acad Sci U S A* 2020; **117**: 17957-64.

385 36. Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2
386 dose in recipients of allogeneic HSCT. *Lancet Haematol* 2021; **8**: e681-3.

387 37. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M*, et al*. Altered B-
388 cell homeostasis and excess BAFF in human chronic graft-versus-host disease. *Blood* 2009; **113**: 3865-
389 74.

390 38. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells
391 after depletion with rituximab in patients with rheumatoid arthritis. *Arthritis Rheum* 2006; **54**: 613-20.

392 39. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral
393 immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. *Blood* 2008; **111**: 5334-41.

394 40. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ*, et al*. Rituximab
395 improves peripheral B cell abnormalities in human systemic lupus erythematosus. *Arthritis Rheum* 2004;
396 **50**: 3580-90.

397 # FIGURE LEGENDS

398 **Fig 1**. Immune response to SARS-CoV-2 mRNA vaccination. The scatter plot shows total
399 immunoglobulin levels for healthy controls, immunodeficient patients and patients after anti-CD20
400 therapy or hematopoietic stem cell transplantation (HSCT). P is <0.001 between all groups calculated
401 with the Kruskal-Wallis test and post hoc analysis. Lines are medians with interquartile range. The Plot
402 was drawn with GraphPad Prism Version 9.2.0.332.

403 **Fig 2**. Correlation of antibody levels determined by Roche anti-SARS-CoV-2 S assay. (A) DiaSorin
404 SARS-CoV-2 TrimericS IgG. (B) Absolute number of B cells ($CD19^+$ cells). (C) Absolute number of
405 naïve B cells. Scatter plots indicate a linear regression line including a 95% confidence interval. In case
406 of A and B, regression line corresponds to transformed data using x=log((x+1) and y=log((y+1)),
407 respectively.

408 **Fig 3**. Exploratory analyses estimating the number of naïve B cells and the interval to the last B-cell
409 depleting therapy required for a vaccination response. (A) The receiver operating characteristic (ROC)
410 analysis curve for naïve B cells differentiating stringent antibody response vs no or any vaccination
411 response in the whole study population (n=199) shows excellent discrimination. (B) A non-linear risk
412 model based on the observed risk of seroconversion was created to estimate the minimum number of
413 naïve B cells required for a stringent vaccination response. Independently, the best discriminatory cut-
414 off (dashed line) was determined with the Youden's index from the ROC curve. Both models predict
415 that ≥60 naïve B cell per µl are required to generate a stringent vaccine response. (C) The ROC analysis
416 curve for the interval since the last B-cell depleting therapy up to 365 days (n=53) differentiating any
417 seroconversion vs no vaccination response. The optimal cut-off is an interval of 116 days or more.


Roche anti-SARS-CoV-2 S total Ig [U/mL]
3000
2000
1000
0
Healthy (n=79)
PID (n=25)
Autoimmune (n=39)
Haematologic (n=56)
Anti-CD20 (n=41)
HSCT (n=35)

Figure 2

A


Roche anti-SARS-CoV-2 S total Ig [U/mL]
2500
2000
1500
1000
500
0
0
500
1000
1500
2000
2500
DiaSorin Anti-Trimeric-S-IgG [BAU/mL]

B


Roche anti-SARS-CoV-2 S total Ig [U/mL]
10,000
1,000
100
10
1
1
10
100
1,000
10,000
CD19+ cells [/µL]

C


Roche anti-SARS-CoV-2 S total Ig [U/mL]
10,000
1,000
100
10
1
1
10
100
1,000
10,000
Naïve B cells [/µL]

Figure 3

A


Sensitivity
0.00
0.25
0.50
0.75
1.00
1 - Specificity
Area under ROC curve = 0.8373

B


0
.1
.2
.3
.4
.5
.6
.7
.8
.9
1
0
500
1000
1500
2000
naive B cells abs [/µL]
Observed Risk
Expected Risk
95% CI

C


Sensitivity
0.00
0.25
0.50
0.75
1.00
1 - Specificity
Area under ROC curve = 0.7716